Personalis (NASDAQ:PSNL) Shares Up 13.1% – Here’s What Happened

Personalis, Inc. (NASDAQ:PSNL) shares rose 13.1% during trading on Monday . The stock traded as high as $15.36 and last traded at $15.9130. 1,267,496 shares were traded during trading, a decline of 42% from the average session volume of 2,201,240 shares. The stock had previously closed at $14.07.

Analyst Ratings Changes

Several brokerages have issued reports on PSNL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Morgan Stanley raised their price target on shares of Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Thursday. BTIG Research dropped their price objective on shares of Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, May 11th. Finally, Wall Street Zen downgraded shares of Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Personalis presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

Personalis Trading Up 9.2%

The company has a market capitalization of $1.61 billion, a PE ratio of -15.10 and a beta of 2.24. The company has a fifty day simple moving average of $9.99 and a 200-day simple moving average of $8.65.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The company had revenue of $15.47 million for the quarter, compared to analysts’ expectations of $14.48 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. On average, equities analysts predict that Personalis, Inc. will post -1.07 EPS for the current fiscal year.

Insider Transactions at Personalis

In other news, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $13.15, for a total value of $1,315,000.00. Following the completion of the sale, the chief executive officer owned 235,986 shares of the company’s stock, valued at $3,103,215.90. This represents a 29.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18. Following the sale, the chief financial officer owned 198,833 shares of the company’s stock, valued at $2,620,618.94. This represents a 20.49% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 435,032 shares of company stock worth $5,599,929 over the last ninety days. 4.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in PSNL. Royal Bank of Canada raised its position in Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after purchasing an additional 2,395 shares during the period. Dynamic Technology Lab Private Ltd raised its holdings in Personalis by 75.6% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock valued at $269,000 after buying an additional 33,044 shares during the period. Goldman Sachs Group Inc. lifted its position in Personalis by 55.7% in the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock valued at $998,000 after buying an additional 101,706 shares during the last quarter. Focus Partners Wealth acquired a new position in Personalis in the first quarter valued at about $47,000. Finally, JPMorgan Chase & Co. boosted its stake in Personalis by 505.6% during the second quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock worth $193,000 after buying an additional 24,621 shares during the period. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.